Starling Oncology, Inc. Current Federal Tax Expense (Benefit)
Starling Oncology, Inc. (DFPH) reported Current Federal Tax Expense (Benefit) of -$99.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-12
- Starling Oncology, Inc. current federal tax expense (benefit) for fiscal 2025 was -$99.00K.
- Starling Oncology, Inc. current federal tax expense (benefit) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Starling Oncology, Inc. current federal tax expense (benefit) for fiscal 2023 was $83.00K.
- Starling Oncology, Inc. current federal tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 12 month | Current Federal Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$99.00K 10-K · filed 2026-03-12 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-12 | |
| 2023-12-31 | $83.00K 10-K · filed 2025-03-26 | |
| 2022-12-31 | $0.00 10-K · filed 2024-03-28 | |
| 2021-12-31 | -$180.00K 10-K · filed 2023-03-16 | |
| 2020-12-31 | $822.00K 10-K · filed 2022-03-11 | $11.43K 10-K · filed 2021-03-30 |